MicroMedical's human heart trials imminent
26 February, 2002 by Tanya HollisAustralia's first artificial hearts are to be implanted in human patients within weeks, according to the developer.
New IMB research targets cystic fybrosis
25 February, 2002 by Pete YoungQueensland bioresearchers have discovered a promising method for treating a common bacterial infection afflicting cystic fibrosis patients.
No GM wheat here: Monsanto
22 February, 2002 by Melissa TrudingerThe Australian branch of agricultural biotechnology giant Monsanto today refuted reports that its herbicide resistant genetically modified wheat seed was taking longer than expected to gain approval in the US.
Heavyweight board a coup for start-up Farmacule
22 February, 2002 by Pete YoungQueensland molecular farming start-up Farmacule Bioindustries has scored a mini-coup by appointing ex-Dow Chemical heavyweight Dr Paul Zorner to its board.
Peptech stands by directors' remuneration
21 February, 2002 by Daniella GoldbergThe Australian Shareholders Association (ASA) has clashed with Sydney biotech company Peptech over the company's remuneration of non-executive board members.
Xenotransplants: not quite around the corner
21 February, 2002 by Daniella GoldbergPig hearts, kidneys and livers could be available for transplant into humans within five to seven years, according to the latest reports from the American Association for the Advancement of Science meeting currently underway in Boston.
Acyte Biotech capitalises on tiny microbes
21 February, 2002 by Daniella GoldbergTwo major multinational pharmaceutical companies and two ASX-listed biotechs are vying for the a new biopharmaceutical platform technology developed by Acyte Biotech, a spin-off company from the University of New South Wales.
Hong Kong destined for best supporting role in biotech
21 February, 2002 by Chee Sing ChanAnalysts and industry experts are widely predicting biotechnology and life sciences to be strong growth areas this year, but in comparison to other Asian markets, Hong Kong seems off the pace.
CSL looks to the US after solid half-year result
21 February, 2002 by Tanya HollisBlood products and vaccine manufacturer CSL has announced it more than doubled its interim profit to $57.5 million on the back of its acquisition of Swiss plasma supplier ZLB last year.
Cochlear bucks uncertainty, meets expectations
21 February, 2002 by Daniella GoldbergCochlear shares gained $A3.90 (+10.1 per cent) to close at $A42.50 on February 18 after half-yearly reports for the six months ended 31 December 2001 showed that the company would meet its long-term growth target of 20 per cent a year.
Ambri prepares its first instrument for market
21 February, 2002 by Daniella GoldbergSydney-based nanotechnology company Ambri Limited is on track to deliver its first biosensor to the Australian market in June, after hooking up with local instrument manufacturer Vision Biosystems.
Florigene gets the Tasmanian blues
21 February, 2002 by Tanya HollisBlue carnations won't be appearing in Tasmanian gardens, after a Melbourne molecular breeder vowed it "would not waste its time" trying to have a GMO ban in the state overturned.
Spirits up at Amrad despite revenue slide
20 February, 2002 by Tanya HollisA promising development pipeline is keeping spirits high at Amrad Corporation despite its posting a $54.6 million drop in revenues in the last half of 2001.
GE free? Don't tell us about it, says Qld govt
20 February, 2002 by Pete YoungVoluntary bans by local farmers are a preferable way of creating GM crop-free areas than passing State laws, says Queensland Premier Peter Beattie.
Interim loss, but EpiTan still in the sun
20 February, 2002 by Tanya HollisThe Melbourne company behind a tanning drug has posted a $1.5 million interim loss as it pushes towards advanced human trials.
